Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A cholesterol drug may slow Alzheimer's before symptoms even start. The new phase 2b SPINOZA trial will test obicetrapib — a CETP inhibitor — in ~400 cognitively healthy adults with early Alzheimer's biomarkers, stratified by APOE genotype. The trial builds on surprising findings from a cardiovascular study showing the drug significantly slowed a key Alzheimer's blood biomarker, with the strongest effects in high-risk APOE4 carriers.
A new phase 2b trial called SPINOZA is putting a cholesterol-targeting drug to the test as a potential Alzheimer's prevention strategy — and the backstory is as compelling as the science. NewAmsterdam Pharma's obicetrapib, a CETP inhibitor originally developed for heart disease, unexpectedly showed it could slow the rise of plasma p-tau217 — a reliable blood biomarker of Alzheimer's pathology — in a substudy of its cardiovascular trial, BROADWAY. Now, the company is taking that signal directly into a dedicated Alzheimer's population.
SPINOZA will enroll ~400 cognitively unimpaired adults aged 55–85 who carry one of three APOE genotypes (E3/E3, E3/E4, or E4/E4) and show early Alzheimer's biomarker changes in blood. Participants will be randomized 1:1 to obicetrapib 10 mg or placebo for 52 weeks, with an optional 26-week open-label extension. The primary endpoint is change in plasma p-tau217 at week 52, with secondary endpoints including amyloid and tau biomarkers and cognitive performance on the PACC5 battery.
By the Numbers:
Why it matters: If obicetrapib can slow Alzheimer's biomarker progression before symptoms appear — especially in genetically high-risk individuals — it could open a new, lipid-focused pathway for early intervention in one of medicine's most challenging diseases.